PT  - JOURNAL ARTICLE
AU  - Atkins, Katherine E.
AU  - Hodgson, David
AU  - Jit, Mark
AU  - Davies, Nicholas G.
TI  - Evaluating the impact of RSV immunisation strategies on antibiotic resistance in England
AID  - 10.1101/2021.11.08.21266072
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.08.21266072
4099  - http://medrxiv.org/content/early/2021/11/09/2021.11.08.21266072.short
4100  - http://medrxiv.org/content/early/2021/11/09/2021.11.08.21266072.full
AB  - Background Vaccines against viruses have been proposed as a novel means to reduce antibiotic use, which would, in turn, decrease selection for antibiotic resistant bacteria. However, the impact of this intervention is poorly quantified, and likely depends on setting-specific epidemiology. Previous studies suggest that up to 20% of antibiotics administered during primary care visits in England are attributable to RSV in some age groups. Therefore, with increasing confidence in a new vaccine against RSV, it is important to quantify the impact of these vaccines on antibiotic prescribing and any downstream reduction in drug resistant bacterial infections.Methods Here we integrate results from a dynamic transmission model of RSV and a statistical attribution framework to capture the impact of RSV vaccines on the reduction in antibiotic prescribing due to averted primary care visits in England.Findings Under base case assumptions, we find that the most impactful RSV vaccine strategy targets children aged 5-14 years, and results in an annual reduction of 7.7 (5.4-9.9) defined daily doses per 1000 person years across the entire population, equivalent to reducing annual all-cause primary care prescribing by 0.23%. Our results suggest that this reduction in antibiotic use would gain 130 DALYs and avert 51,000 GBP associated with drug resistant bacterial infections.Interpretation Even under optimistic conditions, the cost-effectiveness of RSV vaccine strategies in England would likely not be altered by integrating the benefits of preventing drug resistant infections in addition to RSV disease prevention.Funding National Institute for Health Research Health Protection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementN.G.D. and M.J. were funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Immunisation (HPRU-2019-NIHR200929) at the London School of Hygiene and Tropical Medicine and M.J. was funded by the NIHR HPRU in Modelling & Health Economics (HPRU-2019-NIHR200908) at Imperial College and the London School of Hygiene and Tropical Medicine, both in partnership with the UK Health Security Agency. The views expressed are those of the authors and not necessarily those of the NHS, National Institute for Health Research, Department of Health or the UK Health Security Agency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at github.com/katiito/rsvvaccines_amr http://github.com/katiito/rsvvaccines_amr